Plunkett Research Online: Halozyme Therapeutics Inc

HALOZYME THERAPEUTICS INC (HALO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Halozyme Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel oncology therapies that have the potential to improve cancer patient survival. The company’s first commercially-approved product, Hylenex, is based on the patented recombinant human hyal.....



Halozyme Therapeutics Inc
Ticker: HALO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 858-794-8889
Fax: 858-794-5370
Address: 11388 Sorrento Valley Road
San Diego, CA 92121 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceuticals
ContactsDescription
Helen TorleyCEO/Director/President
Laurie StelzerCFO/Chief Accounting Officer/Senior VP
See More
Halozyme Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of novel oncology therapies that have the potential to improve cancer patient survival. The company’s first commercially-approved product, Hylenex, is based on the patented recombinant human hyal.....See More See More

Auditor: Ernst & Young LLP
Legal Advisor: DLA Piper LLP
$USD, In whole numbers,
except marked * or %
201820172016201520142013
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Hylenex
rHuPH20
ENHANZE
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: